Skip to main content
SIBN
NASDAQ Industrial Applications And Services

SI-BONE Tops Q2 Estimates and Lifts 2026 Outlook as Revenue Climbs 15% and Profitability Expands

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$16.86
Mkt Cap
$818.244M
52W Low
$11.48
52W High
$21.89
52W Position info
47% above low
Off High info
23% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

SIBN sits 47% above its 52-week low of $11.48.

Summary

SI-BONE posted Q2 2026 revenue of $56.0 million, beating estimates, and raised its full-year guidance. Adjusted EBITDA turned positive at $2.8 million, and the company highlighted upcoming product and reimbursement tailwinds.

Updates

  1. · Reuters — Stock closed at $17.76 on July 31, below the $23.50 median analyst target.


Key Events · Earnings and Guidance · SIBN

  • Q2 Revenue Beat

    Worldwide revenue of $56.0 million grew 15.2% year-over-year, exceeding the $55.34 million consensus estimate.

  • Raised 2026 Guidance

    Full-year revenue guidance was raised to $231–$233 million (from $230–$233 million), implying roughly 15–16% growth, while operating expense growth is now expected at approximately 12% (down from about 12.5%).

  • Profitability Inflection

    Adjusted EBITDA improved 178% to $2.8 million, and the company generated $0.8 million in positive cash from operations.

  • Upcoming Catalysts

    A 510(k) was submitted for a third breakthrough device targeting a large unmet need in spine surgery; CMS finalized a new MS-DRG family for higher inpatient payments effective October 1.


Analysis · SIBN · Industrial Applications And Services

Second-quarter revenue reached $56.0 million, surpassing the $55.34 million consensus, and full-year 2026 guidance was raised to $231–$233 million. The quarter also marked a swing to positive adjusted EBITDA of $2.8 million—a 178% improvement—and positive cash from operations. Adding to the growth story are a 510(k) submission for a third breakthrough device and a favorable CMS reimbursement ruling that takes effect October 1. Together, accelerating revenue, improving profitability, and upcoming catalysts make this a significant positive update.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.3% of the 1982 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SIBN was trading at $16.86 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $818.2M. The 52-week trading range was $11.48 to $21.89. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SIBN - Latest Insights

SIBN
Nov 03, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $23.77
Real-time Price: $23.44 info
Change: -$0.330 (-1%) info
Market Cap: $1.057B info
SIBN
Nov 02, 2026, 4:09 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.63
Real-time Price: $23.44 info
Change: +$2.81 (+14%) info
Market Cap: $1.057B info
SIBN
Sep 28, 2026, 4:09 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $19.14
Real-time Price: $23.44 info
Change: +$4.30 (+22%) info
Market Cap: $1.057B info
SIBN
Sep 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.39
Real-time Price: $23.44 info
Change: +$4.05 (+21%) info
Market Cap: $1.057B info
SIBN
Aug 04, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $18.44
Real-time Price: $23.44 info
Change: +$5.00 (+27%) info
Market Cap: $1.057B info